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Background: The presence of high microsatellite instability (MSI-H) in colorectal cancers has been
generally associated with better survival, opposite an increased ratio between metastatic lymph-nodes
and nodes sampled in the specimen (LNR) has been associated with a worse outcome. The study aims
to detect the incidence and prognostic signiﬁcance of MSI and LNR in a consecutive series of 119 colo-
rectal cancers.
Methods: 119 consecutive colorectal cancer patients undergone resection at our Department were
enrolled from 2000 to 2004. The MSI status has been evaluated by ampliﬁcation of target sequences. The
LNR has been calculated and patients stratiﬁed into 4 groups on the basis of the ratio values. Clinical/
pathological data were collected and analyzed; the overall, disease free and disease speciﬁc survivals
were analyzed by the KaplaneMeier and Cox regression analyses (mean follow-up: 81 months).
Results: MSI-H was detected in 11.7% of the cases and patients were compared with the microsatellite
stable (MSS) group. We observed a higher prevalence of right colon localizations (p 0.01) and locally
advanced tumors (p 0.0012) in the MSI-H subgroup. KaplaneMeier analysis documented no signiﬁcant
difference comparing MSS patients vs MSI-H, although the latter showed a better survival trend (p ns);
worse survivals were observed according with the LNR stratiﬁcation (p < 0.0001). Multivariate analysis
documented a statistical value associated with the LNR sub-groups in relationship with survival.
Conclusion: According to our results the MSI-H status was associated with particular features (right
locations/locally advanced tumors). The results of a long-term follow-up indicate a trend for better
survival in MSI-H vs MSS patients. Notably, an increased LNR is associated with worse survivals, both at
the univariate and multivariate analysis, displaying this ratio as the strongest prognostic factor of cancer-
related survival.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
According to the Italian Network of Cancer Registries (AIRTUM),
from 1998 to 2002 colonerectal carcinoma has been documented
as the ﬁfth most frequently diagnosed cancer among males and
third among females in Italy,1 whereas in the US it has been clas-
siﬁed as the forth most frequent cancer and the second cause of: þ39 0633775322.
renzon).
ciates Ltd. Published by Elsevier Ltcancer related mortality.2 Because of the epidemiologic impact of
this cancer, several lines of research have been followed in order to
identify signiﬁcant prognostic factors of cancer related mortality or
survival. During the last few years, two opposite prognostic factors
emerged among the multitude: the microsatellite instability and
the lymph-node ratio.
Microsatellites are short DNA sequences consisting of repeti-
tions of a single (mono-), two (di-) or more nucleotides, usually in
the intronic regions of the genes.3 Microsatellite instability (MSI)
has been deﬁned as a change in the number of repetition of these
sequences. MSI is caused by inactivation of the mismatch repaird. All rights reserved.
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(MSH2, MLH1, MSH6 or PMS2)3,4 as in Lynch syndrome or to the
epigenetic silencing of the h-MLH1 gene5e7 as in sporadic colo-
rectal carcinoma. According to the Bethesda guidelines the MSI-H
status has been deﬁned as a mutation in at least two out of the
ﬁve MSI-associated markers, the MSI-low (MSI-L) status has been
deﬁned as a mutation in one marker, whereas tumors could be
considered as stable (MSS) if no mutation could be detected.8 MSI-
H tumors seem to have a distinct phenotype, usually occurring in
the right colon segments (proximal to the splenic ﬂexure); they are
usually characterized by an increased lymphocytic inﬁltration,
mucinous histology and poor differentiation.9,10 Moreover, even
though the data regarding the response to adjuvant chemotherapy
in relationship with the MSI status are controversial, MSI-H tumors
seem to have an improved overall survival.10
On the other hand, the importance of the lymphectomy and the
prognostic impact of the total number of lymph-nodes (Lymph-
Node Harvest, LNH) examined in the surgical specimen after
colectomy has been documented by several studies, and the most
recent guidelines recommend to analyze at least 12 nodes in order
to stage properly colorectal cancers.11,12 Nowadays, a new prog-
nostic factor is emerging in this ﬁeld and regards the ratio between
the total number of positive-metastatic nodes and the total number
of the nodes examined in the surgical specimen (Lymph-Node
Ratio, LNR): in particular an increased ratio seems associated with
a worse survival outcome both for colon and rectal cancer
patients.11,13,14
On the basis of this background, we aimed this study: (a) to the
detection of the MSI status; (b) to the correlation of the MSI status
with the clinical and pathological cancer features (comparing
MSI-H vsMSS patients); and (c) to outline the LNR stratiﬁcation in
a consecutive series of colorectal cancers undergone surgical
resection at our Department. Moreover we correlated the MSI
status and the LNR sub-groups with the overall and cancer-related
survivals of patients reporting results of a long-term 7 years
follow-up.
2. Methods
2.1. Study design, setting and patients
Brieﬂy this study has been designed as a retrospective analysis of prospec-
tively collected data.15 All clinical, pathological and surgical data from 120
consecutive patients undergone surgical resection for colorectal cancer at our
Department from April 2000 to November 2004 were recorded in a prospective
database from the members of the surgical team; the data were thus retrieved
and reviewed for the current analysis. Patients were brieﬂy interviewed on
admission by the members of the surgical team; patients were collected
consecutively and independently of age, sex or tumor location and the only
exclusion criteria was a neo-adjuvant treatment before surgical resection. It is
important to highlight that patients underwent adjuvant treatment (chemo-
therapy in colon cancer patients or chemo-radiotheraphy if rectal cancer
patients) after surgical resection according to the pathological stage of the dis-
ease, patients’ acceptance of the treatments and individual’s performance status.
Authorization of the ethical board was not required for this retrospective study,
but signed consent for the treatment and the evaluation of data was obtained
from all patients before the surgical procedures, along with a consent for
research evaluation on the pathological surgical specimen. Reviewed records
included: patient’s clinical and demographics (age at the time of surgery, sex),
tumor location, type of surgical procedures and adjuvant treatments. The path-
ological data included a brief description (macro/microscopic) of the tumor, a
brief description of the surgical specimen, and the TN category along with the
Stage of the disease. The pathological data also reported the number of sampled
lymph nodes (LNH) and the number of pathological lymph nodes in each
resection, as well as the tumor’s grading. It was then calculated the Lymph-Node
Ratio (LNR) and patients were sub-divided into 4 categories in accordance with
the parameters used by Sjo and co-authors11: LNR1 <0.11, LNR2 0.12e0.18, LNR3
0.19e0.40 and LNR4 >0.41.
Outcome measures were the molecular detection of the MSI through PCR
analysis, the statistical comparison of MSI-H and MSS patients and the survival
analysis by the KaplaneMeier method.2.2. DNA extraction and microsatellite analysis
A fragment of cancer tissue and normal mucosa were collected for each patient.
For each sample of parafﬁn embedded tissue 3 sections of 7 mm were cut and put
on slides, de-waxed, rehydrated and stained with hematoxylin. A pathologist per-
formed the micro-dissection of the normal mucosa and the neoplastic tissue under
microscope using a needle. DNA extractionwas carried-out with 50 ml of lysis buffer
containing 10 mM of proteinase K, overnight digestion at 37 C followed by incu-
bation at 95 C for 10min. After centrifugation the supernatant was stored at20 C.
Microsatellite instability was assessed through PCR using a panel of two mono-
nucleotides (BAT25, primer’s sequences: Fw 50-TCGCCTCCAAGAATGTAAGT-3’REV5’-
TCTGCATTTTAACTATGGCTC-30; BAT26 primer’s sequences: FW 50-TGACTACTTTT-
GACTTCAGCC-30 , REV 50-AACCATTCAACATTTTTAACCC-30; melting temperature:
58 C) targets. Primers were ﬂuorescently labeled. Microsatellite analysis was per-
formed with a genetic analyser ABI3100 (Applied Biosystems, Life Technologies e
Carlsbad, California - US), using GeneScan software to analyze data.
Microsatellite instability was referred as the presence in both loci of extra alleles
in neoplastic tissue compared to matched normal tissue.3
2.3. Follow-up
Follow-up of the patients has been updated yearly by telephone interviews
yearly by the surgical team, with the following end-points: OS (any case of death),
DSS (death due to colorectal cancer), and DFS (ﬁrst recurrence/relapse after surgical
treatment); the last evaluation has been conducted on April 2012.
2.4. Statistical analysis
Sub-groups were compared using the t-Student’s test and c2’s test; all test were
two-tailed and p < 0.05 was considered of statistical signiﬁcance value; Kaplane
Meier survival curves, logrank test for comparison of survival curves and Cox
analysis were obtained using the MedCalc software version 11.4.4.0.
3. Results
3.1. Patients
One patient has been excluded due to peri-operative mortality,
leaving for data analysis 119 patients (73 males, 46 female, M/F
1.58). Mean age at the surgical procedure was of 67 years (median
70; SD 11; range 35e89).
Fourteen cases out 119 (11.7%) showed instability at both
analyzed loci (BAT26 and BAT25) and were therefore regarded as
(MSI-H) cases. In no case was observed instability of only one locus.
Table 1 shows the clinical-pathological features of investigated
patients, comparing MSI-H and stable (MSS) tumors.
Deep extension through the bowel walle T stage - and right side
tumor location showed a signiﬁcant association with the MSI-H
tumors (Chi-square test respectively: p 0.001 and p 0.01); more-
over we noted a trend of younger patients in the MSI-H group
comparing MSS patients (62.14 years vs 67.8 years, T student p
0.08).
Opposite we could not detect a signiﬁcance difference regarding
M/F ratio, Stage, presence of positive nodes in the specimen, LNR,
LNH, tumor’s grading and adjuvant therapies between MSI-H vs
MSS tumors, thus sub-groups appeared to be homogeneous (p ns).
The same trend has been reported analyzing exclusively colon
cancers (excluding rectum localization: 80 patients, 12 MSI-H and
68 MSS), Table 2.
3.2. Survival analysis
Fig. 1 shows the Kaplan Meier survival curves regarding
colorectal cancer patients. Mean follow up was of 81.0 months
(median 80, range: 21e144 months). According with our ﬁndings,
we documented a better survival trend for the MSI-H patients
comparing with MSS patients, regarding overall, disease free and
disease speciﬁc survivals, none of theme, however, reaching
signiﬁcance. Opposite we documented a statistical signiﬁcance
difference stratifying patients according with the LNR sub-
Table 2
Clinical and pathological features of 80 consecutive colon cancer patients undergone
surgical resection: comparison between MSI-H vs MSS sub-groups (MSI-H: micro-
satellite high; MSS: microsatellite stable).
MSI-H (1 patients) MSS (patients) p
Sex e n (%)
M 6 (50%) 36 (52.9%) 0.9b
F 6 (50%) 32 (47.1%)
M/F 1 1.125
Age (years)
Mean 61.0 68.6 0.04c
Median, SD 66, 14.5 71, 10.8
Range, 95% C.I 35e80, 52.3e69.8 35e89, 66.0e71.2
Localization n (%)
Right 8 (66.7%) 20 (29.4%) 0.03b
Transverse 0 () 6 (8.9%)
Sigmoid 4 (33.3%) 42 (61.7%)
Stage n (%)
I 0 () 9 (13.2%) 0.25b
II 5 (41.7%) 25 (36.8%)
III 7 (58.3%) 26 (38.2%)
IV 0 () 8 (11.8%)
Adjuvant and Neo-adjuvant treatments n (%)
Yes 8 (66.7%) 28 (41.2%) 0.25b
No 4 (33.3%) 40 (58.8%)
T Stage n (%)
1 0 () 2 (2.9%) 0.006b
2 0 () 9 (13.2%)
3 4 (33.3%) 44 (64.7%)
4 8 (66.7%) 13 (19.2%)
N Stage n (%)
þ 7 (41.7%) 33 (48.5%) 0.75b
 5 (58.3%) 35 (51.5%)
Grading n (%)
1 0 () 13 (19.2%) 0.23b
2 8 (66.7%) 40 (58.8%)
3 4 (33.3%) 15 (22.0%)
4 0 () 0 ()
Lymph node ratioa n (%)
LNR1 <0.11 6 (60.0%) 36 (64.3%) 0.59b
LNR2 0.12e0.18 1 (10.0%) 3 (5.3%)
LNR3 0.19e0.40 1 (10.0%) 12 (21.4%)
LNR4 >0.41 2 (20.0%) 5 (9.0%)
Follow-up (months)
Mean 82.3 77.0 0.65c
Median, SD 83.0, 29.1 77.0, 31.6
Range, 95% C.I. 38e136, 59.9e104.7 18e137, 65.6e88.4
Lymph node harvesta (n)
Mean 16.4 18.0 0.58c
Median, SD 15.5, 7.0 16.5, 8.9
Range, 95% C.I. 5e28, 11.3e21.4 4e42, 15.6e20.4
a Data available on 66 patients (MSI-H and 56 MSS).
b Chi-square test.
c Tstudent test.
Table 1
Clinical and pathological features of 119 consecutive colorectal cancer patients
undergone surgical resection: comparison between MSI-H patients vsMSS patients
(MSI-H: microsatellite high; MSS: microsatellite stable).
MSI-H (14 patients) MSS (105 patients) p
Sex e n (%)
M 7 (50.0%) 66 (62.8%) 0.52c
F 7 (50.0%) 39 (37.2%)
M/F 1 1.7
Age (years)
Mean 62.14 67.8 0.08d
Median, SD 68.5, 14.6 70, 10.8
Range, 95% C.I 35e80, 53.7e70.6 38e89, 65.7e69.9
Localization n (%)
Right 8 (57.1%) 20 (19.0%) 0.01c
Transverse e 6 (5.7%)
Sigmoid 4 (28.6%) 42 (40.0%)
Rectum 2 (14.3%) 37 (35.3%)
Stage n (%)
I 1 (7.2%) 19 (18.0%) 0.21c
II 5 (35.7%) 36 (34.3%)
III 8 (57.1%) 36 (34.3%)
IV e 14 (13.4%)
Adjuvant and Neo-adjuvant treatmentsa n (%)
Yes 9 (64.3%) 46 (44.3%) 0.26c
No 5 (35.7%) 58 (55.7%)
T Stage n (%)
1 e 5 (4.8%) 0.001c
2 1 (7.2%) 17 (16.2%)
3 4 (28.6%) 65 (61.9%)
4 9 (64.2%) 18 (17.1%)
N Stage n (%)
þ 8 (57.1%) 48 (45.7%) 0.60c
 6 (42.9%) 57 (54.3%)
Grading n (%)
1 e 18 (17.1%) 0.21c
2 10 (71.4%) 67 (63.8%)
3 4 (28.6%) 20 (19.1%)
4 e e
Lymph node ratiob n (%)
LNR1 <0.11 7 (58.3%) 59 (68.6%) 0.51c
LNR2 0.12e0.18 2 (16.7%) 6 (6.9%)
LNR3 0.19e0.40 1 (8.3%) 13 (15.1%)
LNR4 >0.41 2 (16.7%) 8 (9.4%)
Follow-up (months)
Mean 83.3 79.1 0.71d
Median, SD 83.5, 27.6 78, 33.8
Range, 95% C.I. 38e136, 63.5e103.0 21e144, 69.8e88.5
Lymph node harvestb (n)
Mean 15.4 17.8 0.36d
Median, SD 14, 6.9 16, 8.6
Range, 95% C.I. 6e28, 11.0e19.8 4e43, 15.9e19.6
a Data available on 118 patients (14 MSI-H and 104 MSS).
b Data available on 98 patients (12 MSI-H and 86 MSS).
c Chi-square test.
d T student test.
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documented that LNR is an independent prognostic factor asso-
ciated with survivals (Table 3). Similar ﬁndings were noted
analyzing exclusively colon cancers (excluding rectum localiza-
tion: 80 patients, 12 MSI-H and 68 MSS), regarding survivals -
Fig. 2 e and multivariate analysis (with the exception of disease
free survival) e Table 4.4. Discussion
During the last few years, a number of prognostic factors
emerged in the ﬁeld of colorectal cancer research. Indeed we
recently investigated the impact of the T4 sub-stratiﬁcation ac-
cording with the new AJCC classiﬁcation and the prognostic value
of the LNH in Stage II colorectal cancers.16,17We aimed this study to the detection and to the validation of the
prognostic impact of the MSI and the LNR in a consecutive series of
colorectal cancer patients. Among the multitude of prognostic
factors emerged in the recent years, we selected these ones since
past studies documented that might have opposite implications;
indeed the detection of a MSI-H status has been associated with a
better prognosis, otherwise an increased LNR has been correlated
with a worse outcome.8,11 Moreover, to the best of our knowledge,
published literature lacks of studies investigating these two cova-
riates together in a multivariate analysis.
In our consecutive series of 119 colorectal cancer patients, we
detected an 11.7% of MSI-H tumors; we investigated MSI using a
panel of twomononucleotide markers that have been shown as the
most sensitive and speciﬁc to identify colorectal tumors harboring
real mismatch repair system deﬁciency in large population series.18
The incidence of MSI-H in our series is in agreement with pre-
vious reports. Moreover according with past studies, MSI-H tumors
were more frequent located in the right colon segments, and
Fig. 1. Colorectal cancer and survivals (n 119 patients). a. Overall Survival, Disease Free Survival and Disease Speciﬁc Survival, MSI-H patients vs MSS patients (MSI-H: microsatellite
high; MSS: microsatellite stable); b. Overall Survival, Disease Free Survival and Disease Speciﬁc Survival according to the LNR sub-groups.
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difference did not reach a statistical value); opposite we could not
detect a difference in the stage classiﬁcation between sub-
groups.9,19Table 3
Cox regression analysis conducted on 119 colorectal cancer patients with the end-
points of Overall Survival, Disease Free Survival and Disease Speciﬁc Survival.
p 95% CI of Exp(b)
Overall Survival
Age 0.29 0.6618e3.8970
Grading 0.26 0.7214e3.3360
MSI 0.11 0.1033e1.2891
LNR 0.001 1.7391e10.2813
Localization 0.01 1.1951e6.4387
N Stage 0.96 0.0000e7.71Eþ183
Sex 0.20 0.7668e3.4293
Stage 0.96 0.0000e156Eþ174
T Stage 0.11 0.8002e8.0230
Disease Free Survival
Age 0.89 0.4054e2.7941
Grading 0.38 0.6090e3.6543
MSI 0.10 0.0608e1.2801
LNR 0.009 1.3960e10.1267
Localization 0.21 0.6916e5.3063
N Stage 0.96 0.0000e37.6Eþ180
Sex 0.16 0.7710e4.9432
Stage 0.96 0.0000e78.4Eþ171
T Stage 0.15 0.5769e36.6471
Disease Speciﬁc Survival
Age 0.69 0.4241e3.6198
Grading 0.35 0.5679e4.8487
MSI 0.12 0.0563e1.3978
LNR 0.001 2.0778e22.5588
Localization 0.13 0.7473e9.9086
N Stage 0.97 0.0000e3.67Eþ222
Sex 0.42 0.5546e4.1227
Stage 0.97 0.0000e52.7Eþ213
T Stage 0.13 0.6010e41.7093
Bold represents statistical signiﬁcant values.Indeed our survival analysis in relationship with the MSI status
is in agreement with the ﬁndings recently reported by Kim and
associates: authors documented that MSI patients had a peculiar
clinic-pathological features, but these subsets did not impact the
overall and disease-free survival rate.20 Moreover authors docu-
mented a signiﬁcant association with the T stage of the disease and
the MSI status, in agreement with our results.20
Indeed the same trend of survival has been reported by
Azzoni and co-authors: they documented an improved overall
and disease speciﬁc survival trend for MSI-H patients comparing
MSI-L and MSS patients, but the difference did not reach a sta-
tistical value.21
Overall, the published literature concerning the relationship
between OS and MSI status has been reviewed in 2005, including
more than 7000 colorectal cancer patients from 32 different
studies: the OS hazard ratio (HR) associated with the MSI status
has been reported of 0.65 (95% CI, 0.59e0.71); the MSI-H patients
had a better prognosis even if the data were restricted to clinical
trial patients and those with locally advanced colorectal
cancers.22
On the other hand, we based the LNR stratiﬁcation according
with Sjo and co-authors: they documented an association be-
tween a LNH > 12 and OS in colon cancer patients with Stage II of
disease, however in patients with Stage III of disease an increased
LNR was correlated with a reduced OS and time to recurrence
both at the univariate and at the multivariate analyses.11 Simi-
larly Persiani and associates identiﬁed in the Log odds of positive
nodes (the log of the ratio between the number of positive and
negative lymph nodes) as an independent prognostic factor of
survival in a series of 258 colon cancer patients.23 Moreover the
LNR has been associated with survival prognosis even in node-
positive rectal cancer patients,14 undergone total mesorectal
excision followed by chemotherapy.24 Indeed the LNR was found
to be an independent prognostic factor for Stage III colorectal
cancer patients in a study reporting a 10 years survival analysis.25
Fig. 2. Colon cancer and survivals (n 80 patients). a. Overall Survival, Disease Free Survival and Disease Speciﬁc Survival, MSI-H patients vsMSS patients (MSI-H: microsatellite high;
MSS: microsatellite stable); b. Overall Survival, Disease Free Survival and Disease Speciﬁc Survival according to the LNR sub-groups.
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results analyzing either colorectal cancer patients or exclusively
colon cancer patients, regarding the clinical-pathological features
and the prognosis of the MSI-H group vs MSS patients (trend ofTable 4
Cox regression analysis conducted on 80 colon cancer patients with the end-points
of Overall Survival, Disease Free Survival and Disease Speciﬁc Survival.
p 95% CI of Exp(b)
Overall Survival
Age 0.29 0.5918e5.8160
Grading 0.48 0.5875e3.0986
MSI 0.06 0.0420e1.1051
LNR 0.008 1.5131e17.3473
Localization 0.03 1.1052e10.1759
N Stage 0.96 0.0000e189Eþ186
Sex 0.11 0.8269e5.5901
Stage 0.96 0.0000e5.72Eþ180
T Stage 0.17 0.6076e15.3894
Disease Free Survival
Age 0.25 0.5937e7.1252
Grading 0.81 0.4388e2.8615
MSI 0.08 0.0437e1.2030
LNR 0.15 0.7203e7.5684
Localization 0.47 0.4843e4.7153
N Stage 0.95 0.0000e1.01Eþ180
Sex 0.10 0.8097e8.5078
Stage 0.96 0.0000e2.17Eþ171
T Stage 0.50 0.2382e18.2243
Disease Speciﬁc Survival
Age 0.54 0.3929e5.8393
Grading 0.44 0.4737e5.5215
MSI 0.26 0.0804e1.9773
LNR 0.04 1.0164e19.7835
Localization 0.38 0.4551e7.7092
N Stage 0.97 0.0000e61.2Eþ210
Sex 0.81 0.3163e4.3226
Stage 0.97 0.0000e1.62Eþ204
T Stage 0.60 0.1969e16.1681
Bold represents statistical signiﬁcant values.survivals, the tumor location and the T stage of the tumor);
remarkably a signiﬁcant difference between ages was noted
considering the colon cancer patients, otherwise in the cumula-
tive series of colorectal cancer patients MSI-H patients were
noted to be younger comparing controls, no reaching however a
statistical value (Figs. 1 and 2, Tables 1 and 2). Moreover the
multivariate analysis provided similar results, displaying the LNR
as the only independent prognostic factor related to survivals in
the colorectal cancer patients, and related to the overall survival
and disease speciﬁc survival in the colon cancer series (Tables 3
and 4).
A possible limitation of the present study regards the relative
small sample analyzed. Moreover the investigation of the MSI
status done with two highly sensitive mononucleotide markers
could have missed MSI-L group. Several studies reported, however,
that the BAT26 and BAT25 were the most speciﬁc and sensitive
markers in order to assess colorectal tumors with defective
mismatch repair system.26,27 Furthermore MSI-L colorectal carci-
nomas do not seem to differ from MSS cancer in terms of under-
lying genetic pathway and clinical-pathological features28 and past
pooled analysis grouped together the MSI-L and MSS patients,22 so
we could assume that this limitation did not interferewith theMSI-
H vs MSS comparison analysis.
It is important to underline that in this study we present results
of a long-term follow-up analysis that lasted about 7 years.
In conclusion, in this case series MSI-H status has been detected
in the 11.7% of the cases and it has been associated with particular
features (right locations/locally advanced tumors). MoreoverMSI-H
colon cancer patients were noted to be younger comparing with
controls.
The results of a long-term follow-up indicate a trend for better
survival in MSI-H vs MSS patients. Notably, an increased LNR has
been associated with worse survivals, both at the univariate and
multivariate analysis, displaying this ratio as the strongest prog-
nostic factor of cancer-related survival.
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